Filing Flows › Angiodynamics (ANGO) › R&D spending
Angiodynamics (ANGO) R&D spending by quarter
Angiodynamics' R&D spending was $8.0M in Q1 FY27 (first quarter fiscal 2027), -2% from Q4 FY26. Over the last 7 quarters it ranged from $6.4M (Q1 FY26) to $8.2M (Q4 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY27 | $8.0M | -2% | +24% |
| Q4 FY26 | $8.2M | +15% | +24% |
| Q3 FY26 | $7.1M | -9% | +2% |
| Q2 FY26 | $7.8M | +21% | — |
| Q1 FY26 | $6.4M | -3% | — |
| Q4 FY25 | $6.6M | -5% | — |
| Q3 FY25 | $6.9M | — | — |
Q1 FY27 at a glance
Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%, net loss $7.1M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Angiodynamics' R&D spending?
Angiodynamics' R&D spending was $8.0M in Q1 FY27 (first quarter fiscal 2027), -2% from Q4 FY26.
How has Angiodynamics' R&D spending changed?
Over the last 7 quarters it ranged from $6.4M (Q1 FY26) to $8.2M (Q4 FY26).